Itra100 mg

Itra 100 mg is indicated in- Tinea corporis, Tinea cruris, Tinea pedis, Tinea manus, Vulvovaginal candidiasis, Fungal keratitis, Pityriasis versicolor, Oropharyngeal candidiasis, Onychomycosis, Histoplasmosis, Systemic Infections: (Aspergillosis, Candidiasis and Cryptococcus when other drugs are effective) ... Read moreItra 100 mg is indicated in- Tinea corporis, Tinea cruris, Tinea pedis, Tinea manus, Vulvovaginal candidiasis, Fungal keratitis, Pityriasis versicolor, Oropharyngeal candidiasis, Onychomycosis, Histoplasmosis, Systemic Infections: (Aspergillosis, Candidiasis and Cryptococcus when other drugs are effective) Antifungal prophylaxis: To prevent systemic fungal infection in severely neutropenic patients.

Drugs for subcutaneous and mycoses

Itra 100 mg is an orally active triazole antifungal drug that has demonstrated a broad spectrum of activity and favorable pharmacokinetic profile. Itra 100 mg inhibits Cytochrome P-450 dependent enzymes resulting in impairment of the biosynthesis of ergosterol, a major component of the cell membrane of yeast and fungal cells. Being integral to the proper functioning of the cell membrane, inhibition of the synthesis of ergosterol leads to a cascade of abnormalities in permeability, membrane bound enzyme activity, and co-ordination of chitin synthesis leading to inhibition of growth, abnormal cell wall formation and accumulation of intracellular lipids and membranous vesicles.

Tinea corporis, Tinea cruris: 100 mg daily for 2 weeks.Tinea pedis, Tinea manus: 100 mg daily for 4 weeks.Vulvovaginal candidiasis: 200 mg twice daily for 1 day or 200 mg daily for 3 days.Fungal keratitis: 200 mg daily for 3 weeks.Pityriasis versicolor: 200 mg daily for 1 week.Oropharyngeal candidiasis: 100 mg daily (200 mg for AIDS patients) for 15 days.Onychomycosis: 200 mg daily for 3 months; or 200 mg twice daily for 7 days (course), subsequent courses repeated after 21 day interval; fingernails 2 courses and toenails 3 courses.Histoplasmosis: 200 mg 1-2 times daily.Systemic Infections: (Aspergillosis, Candidiasis and Cryptococcus when other drugs are effective) 200 mg once daily, increased in invasive or in cryptococcal meningitis to 200 mg twice daily.Antifungal prophylaxis: To prevent systemic fungal infection in severely neutropenic patients: 100mg daily. Or as directed by the physician.

Should be taken with food. Take immediately after a full meal.

Itra 100 mg inhibits the metabolism of Cyclosporine and Warfarin. Interaction with Terfenadine, Phenobarbitone, Midazolam has been reported.

The drug is contraindicated in patients with a known history of hypersensitivity to it. The drug is also contraindicated in pregnant women and patients with known severe hepatic disease. It is also contraindicated with Rifampicin therapy.

Nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, hepatitis, cholestatic jaundice, peripheral neuropathy have been reported.

Itra 100 mg is contraindicated in pregnancy. Breast feeding while receiving Itra 100 mg is not recommended.

Hepatic enzyme value should be monitored in patients with preexisting hepatic function abnormalities. It should also be done periodically in all patients receiving continuous treatment for more than one month or at any time a patients develops sign and symptoms suggestive liver dysfunction.

There is no experience of overdosage with Itra 100 mg.

Store below 30°C, away from light & in a dry place. Keep out of the reach of children.

Drugs for subcutaneous and mycoses

Itra 100 mg is an orally active triazole antifungal agent, having broad-spectrum activity and a favourable pharmacokinetic profile. Itra 100 mg inhibits cytochrome p-450 dependent enzymes resulting in impairment of the biosynthesis of ergoesterol, a major component of the cell membrane of yeast and fungal cells.

Not recommended during pregnancy & lactation, unless otherwise indicated by the physician.

The efficacy and safety of the Itra 100 mg capsule have not been established in pediatric patients.